Kate T. Simms (Australia)
Cancer Council New South Wales Cancer Research Division
Presenter of 1 Presentation
POPULATION-LEVEL EFFECTIVENESS AND COST-EFFECTIVENESS OF HPV-FASTER IN TWO EXAMPLE COUNTRIES WITHOUT AN EXISTING VACCINATION PROGRAM: MODELLED EVALUATION OF CHINA AND VIETNAM (ID 704)
Session Time
13:15 - 14:45
Session Type
Public Health Oral Session
Lecture Time
14:30 - 14:42
[{"name":"POPULATION-LEVEL EFFECTIVENESS AND COST-EFFECTIVENESS OF HPV-FASTER IN TWO EXAMPLE COUNTRIES WITHOUT AN EXISTING VACCINATION PROGRAM: MODELLED EVALUATION OF CHINA AND VIETNAM \u003Csmall\u003E(ID 704)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":704,"presentation":"POPULATION-LEVEL EFFECTIVENESS AND COST-EFFECTIVENESS OF HPV-FASTER IN TWO EXAMPLE COUNTRIES WITHOUT AN EXISTING VACCINATION PROGRAM: MODELLED EVALUATION OF CHINA AND VIETNAM \u003Csmall\u003E(ID 704)\u003C\/small\u003E","session":"Oral Session 1: MODELLING I. Modelling and economic analyses for cervical cancer elimination","presenter":"Kate T. Simms (Australia)","photo":""},"playlist":[{"name":"POPULATION-LEVEL EFFECTIVENESS AND COST-EFFECTIVENESS OF HPV-FASTER IN TWO EXAMPLE COUNTRIES WITHOUT","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/Kate-Simms_IPVC 704.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/67\/Kate-Simms_IPVC 704.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/AD0A3967.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/Kate-Simms_IPVC 704.vtt"}]}]
{"provider":"CTI","provider_live":0,"type":1,"code":"6E22UU0d9"}
[session]
[presentation]
[presenter]
Moderator of 1 Session
Session Type
Public Health Oral Session
Session Time
13:15 - 14:45
[{"name":"CERVICAL CANCER ELIMINATION IN LOW AND MIDDLE INCOME COUNTRIES: THE FLOW-ON BENEFITS OF PREVENTING THE LOSS OF A MOTHER ON THE FAMILY \u003Csmall\u003E(ID 701)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":701,"presentation":"CERVICAL CANCER ELIMINATION IN LOW AND MIDDLE INCOME COUNTRIES: THE FLOW-ON BENEFITS OF PREVENTING THE LOSS OF A MOTHER ON THE FAMILY \u003Csmall\u003E(ID 701)\u003C\/small\u003E","session":"Oral Session 1: MODELLING I. Modelling and economic analyses for cervical cancer elimination","presenter":"James Killen (Australia)","photo":""},"playlist":[{"name":"CERVICAL CANCER ELIMINATION IN LOW AND MIDDLE INCOME COUNTRIES: THE FLOW-ON BENEFITS OF PREVENTING T","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/GMT20200709-044955_James-Kill_1920x1080-0.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/67\/GMT20200709-044955_James-Kill_1920x1080-0.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/3651557A.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/GMT20200709-044955_James-Kill_1920x1080-0.vtt"}]},{"name":"COST-EFFECTIVENESS OF SCALED-UP HPV VACCINATION AND SCREENING TO ACHIEVE CERVICAL CANCER ELIMINATION IN THE UNITED STATES \u003Csmall\u003E(ID 676)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":676,"presentation":"COST-EFFECTIVENESS OF SCALED-UP HPV VACCINATION AND SCREENING TO ACHIEVE CERVICAL CANCER ELIMINATION IN THE UNITED STATES \u003Csmall\u003E(ID 676)\u003C\/small\u003E","session":"Oral Session 1: MODELLING I. Modelling and economic analyses for cervical cancer elimination","presenter":"Megan A. Smith (Australia)","photo":""},"playlist":[{"name":"COST-EFFECTIVENESS OF SCALED-UP HPV VACCINATION AND SCREENING TO ACHIEVE CERVICAL CANCER ELIMINATION","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/Megan-Smit_1920x1080.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/67\/Megan-Smit_1920x1080.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/4CAAA114.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/Megan-Smit_1920x1080.vtt"}]},{"name":"THE COST-EFFECTIVENESS PROFILE OF SEX-NEUTRAL HPV IMMUNIZATION IN EUROPEAN TENDER-BASED SETTINGS \u003Csmall\u003E(ID 805)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":805,"presentation":"THE COST-EFFECTIVENESS PROFILE OF SEX-NEUTRAL HPV IMMUNIZATION IN EUROPEAN TENDER-BASED SETTINGS \u003Csmall\u003E(ID 805)\u003C\/small\u003E","session":"Oral Session 1: MODELLING I. Modelling and economic analyses for cervical cancer elimination","presenter":"Johannes A. Bogaards (Netherlands)","photo":""},"playlist":[{"name":"THE COST-EFFECTIVENESS PROFILE OF SEX-NEUTRAL HPV IMMUNIZATION IN EUROPEAN TENDER-BASED SETTINGS","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/GMT20200706-075027_Hans-Bogaa_1686x768-0.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/67\/GMT20200706-075027_Hans-Bogaa_1686x768-0.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/5282AC2F.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/GMT20200706-075027_Hans-Bogaa_1686x768-0.vtt"}]},{"name":"GLOBAL IMPACT AND COST-EFFECTIVENESS OF ONE-DOSE VERSUS TWO-DOSE HUMAN PAPILLOMAVIRUS VACCINATION SCHEDULES: AN EXPLORATORY MODELLING ANALYSIS \u003Csmall\u003E(ID 1048)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1048,"presentation":"GLOBAL IMPACT AND COST-EFFECTIVENESS OF ONE-DOSE VERSUS TWO-DOSE HUMAN PAPILLOMAVIRUS VACCINATION SCHEDULES: AN EXPLORATORY MODELLING ANALYSIS \u003Csmall\u003E(ID 1048)\u003C\/small\u003E","session":"Oral Session 1: MODELLING I. Modelling and economic analyses for cervical cancer elimination","presenter":"Kiesha Prem (United Kingdom)","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/ipvc20\/persons\/photos\/3193.jpg"},"playlist":[{"name":"GLOBAL IMPACT AND COST-EFFECTIVENESS OF ONE-DOSE VERSUS TWO-DOSE HUMAN PAPILLOMAVIRUS VACCINATION SC","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/Kiesha Prem - IPVC20 - PRESENTATION id 1048.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/67\/Kiesha Prem - IPVC20 - PRESENTATION id 1048.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/C677A060.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/Kiesha Prem - IPVC20 - PRESENTATION id 1048.vtt"}]},{"name":"THE IMPACT AND COST-EFFECTIVENESS OF SINGLE-DOSE HPV VACCINATION IN UGANDA: A COMPARATIVE MODELING ANALYSIS \u003Csmall\u003E(ID 1206)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1206,"presentation":"THE IMPACT AND COST-EFFECTIVENESS OF SINGLE-DOSE HPV VACCINATION IN UGANDA: A COMPARATIVE MODELING ANALYSIS \u003Csmall\u003E(ID 1206)\u003C\/small\u003E","session":"Oral Session 1: MODELLING I. Modelling and economic analyses for cervical cancer elimination","presenter":"Emily A. Burger (United States of America)","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/ipvc20\/persons\/photos\/695.jpg"},"playlist":[{"name":"THE IMPACT AND COST-EFFECTIVENESS OF SINGLE-DOSE HPV VACCINATION IN UGANDA: A COMPARATIVE MODELING A","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/1206 Emily Burger.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/67\/1206 Emily Burger.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/72CBD7EB.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/1206 Emily Burger.vtt"}]},{"name":"IMPACT AND TRADEOFFS OF HUMAN PAPILLOMAVIRUS (HPV) VACCINATION AND SCREENING CHANGES ON CERVICAL CANCER ELIMINATION IN NORWAY \u003Csmall\u003E(ID 302)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":302,"presentation":"IMPACT AND TRADEOFFS OF HUMAN PAPILLOMAVIRUS (HPV) VACCINATION AND SCREENING CHANGES ON CERVICAL CANCER ELIMINATION IN NORWAY \u003Csmall\u003E(ID 302)\u003C\/small\u003E","session":"Oral Session 1: MODELLING I. Modelling and economic analyses for cervical cancer elimination","presenter":"Allison Portnoy (United States of America)","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/ipvc20\/persons\/photos\/692.jpg"},"playlist":[{"name":"IMPACT AND TRADEOFFS OF HUMAN PAPILLOMAVIRUS (HPV) VACCINATION AND SCREENING CHANGES ON CERVICAL CAN","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/Allison Portnoy 302.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/67\/Allison Portnoy 302.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/8192FA8D.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/Allison Portnoy 302.vtt"}]},{"name":"POPULATION-LEVEL EFFECTIVENESS AND COST-EFFECTIVENESS OF HPV-FASTER IN TWO EXAMPLE COUNTRIES WITHOUT AN EXISTING VACCINATION PROGRAM: MODELLED EVALUATION OF CHINA AND VIETNAM \u003Csmall\u003E(ID 704)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":704,"presentation":"POPULATION-LEVEL EFFECTIVENESS AND COST-EFFECTIVENESS OF HPV-FASTER IN TWO EXAMPLE COUNTRIES WITHOUT AN EXISTING VACCINATION PROGRAM: MODELLED EVALUATION OF CHINA AND VIETNAM \u003Csmall\u003E(ID 704)\u003C\/small\u003E","session":"Oral Session 1: MODELLING I. Modelling and economic analyses for cervical cancer elimination","presenter":"Kate T. Simms (Australia)","photo":""},"playlist":[{"name":"POPULATION-LEVEL EFFECTIVENESS AND COST-EFFECTIVENESS OF HPV-FASTER IN TWO EXAMPLE COUNTRIES WITHOUT","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/Kate-Simms_IPVC 704.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/67\/Kate-Simms_IPVC 704.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/AD0A3967.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/67\/Kate-Simms_IPVC 704.vtt"}]}]
{"type":2,"code":"aE32UU02a"}
[session]
[presentation]
[presenter]
